Rapport Therapeutics (RAPP) EBT Margin (2026)
Rapport Therapeutics (RAPP) posted quarterly EBT Margin of 718.46% for Q1 2026.
Powered by 
Analysis
Rapport Therapeutics (RAPP) EBT Margin (2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported EBT Margin for 1 consecutive years, with 718.46% the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 12.09% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -2.67% |
| 10 | Rapport Therapeutics | 2.22 Bn | 2.22 Bn | - | - |